Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: Discrete event simulation

Current Medical Research and Opinion

Volumn 26, Issue 1, 2010, Pages 17-24

  Kongnakorn, Thitima ^a   Mwamburi, Mkaya ^a,b   Merchant, Sanjay ^c   Akhras, Kasem ^c   Caro, J Jaime ^a,d   Nathwani, Dilip ^e  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cost effectiveness; Doripenem; Nosocomial pneumonia; Ventilator associated pneumonia

Indexed keywords

DORIPENEM; IMIPENEM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ARTIFICIAL VENTILATION; CLINICAL PRACTICE; DISEASE TRANSMISSION; DRUG EFFICACY; HEALTH CARE SYSTEM; HOSPITAL COST; HOSPITAL MANAGEMENT; HOSPITAL SERVICE; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INFECTION RISK; INTENSIVE CARE UNIT; LENGTH OF STAY; MORTALITY; NOSOCOMIAL PNEUMONIA; PNEUMONIA; PSEUDOMONAS INFECTION; REVIEW; SEIZURE; SIMULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; ARTICLE; CROSS INFECTION; ECONOMICS; VALIDATION STUDY;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; CROSS INFECTION; HUMANS; PNEUMONIA; UNITED STATES;

EID: 77649220274     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903358980     Document Type: Review

References (35)

1. Tablan OC, Anderson LJ, Besser R, et al. Healthcare Infection Control Practices Advisory Committee, Centers for Disease Control and Prevention. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004:53(RR-3):1-36
2. Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8 (Pubitemid 23074802)
3. Leu HS, Kaiser DL, Mori M, et al. Hospital-acquired pneumonia: attributable mortality and morbidity. Am J Epidemiol 1989;129:1258-67 (Pubitemid 19148466)
4. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903 (Pubitemid 34774654)
5. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122: 2115-21 (Pubitemid 36051151)
6. American Thoracic Society, Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilatorassociated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
7. J Rello. Bench-to-bedside review: therapeutic options and issues in the management of ventilator-associated bacterial pneumonia. Crit Care 2005; 9:259-65 (Pubitemid 40796803)
8. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005;11(Suppl. 4):17-32 (Pubitemid 40946169)
9. Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother 2003; 51:347-52 (Pubitemid 36231155)
10. Infectious Diseases Society of America. Bad bugs, no drugs. Policy Report, 2004
11. Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36: 1089-96 (Pubitemid 351482655)
12. Réa-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008;24:2113-26
13. Merchant S, Gast C, Nathwani D, et al. Hospital Resource Utilization with Doripenem Versus Imipenem in the Treatment of Ventilator-Associated Pneumonia. Clin Ther 2008;30:771-33
14. Kelton WD, Sadowski RP, Sadowski DA. Simulation with ARENA, 3rd edn. Boston, MA: McGraw-Hill, 2003
15. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005;23:323-32 (Pubitemid 40677051)
16. AnalySource and National Drug Data File (NDDF) data and copyrighted by First DataBank, Inc. 2007
17. Dasta JF, McLaughlin TP, Mody S, et al. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med 2005; 33:1266-71 (Pubitemid 40827376)
18. Paladino JA, Adelman MH, Schentag JJ, et al. Direct costs in patients hospitalized with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US. Pharmacoeconomics 2007;25:677-83 (Pubitemid 47124169)
19. Consumer Price Index reports. Bureau of Labor Statistics. U.S. Department of Labor, 2007
20. Carmeli Y, Troillet N, Karchmer AW, et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159:1127-32 (Pubitemid 29230866)
21. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford University Press, 2005
22. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999;27:887-92 (Pubitemid 29266004)
23. Fagon JY, Chastre J, Hance AJ, et al. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993;94:281-8 (Pubitemid 23074802)
24. Kollef MH. Ventilator-associated pneumonia. A multivariate analysis. JAMA 1993;270:1965-70
25. Ost DE, Hall CS, Joseph G, et al. Decision analysis of antibiotic and diagnostic strategies in ventilator-associated pneumonia. Am J Respir Crit Care Med 2003;168:1060-7 (Pubitemid 37338934)
26. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122:262-8 (Pubitemid 34754172)
27. Alvarez-Lerma F, Alvarez B, Luque P, et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006;10:R78
28. Diaz E, Munoz E, Agbaht K, et al. Management of ventilator-associated pneumonia caused by multiresistant bacteria. Curr Opin Crit Care 2007;13:45-50 (Pubitemid 46052169)
29. Gastmeier P, Sohr D, Geffers C, et al. Risk factors for death due to nosocomial infection in intensive care unit patients: findings from the Krankenhaus Infektions Surveillance System. Infect Control Hosp Epidemiol 2007;28: 466-72 (Pubitemid 46658061)
30. Attanasioa E, Russo P, Carunchio G, et al. Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections. Dig Surg 2000;17:164-72 (Pubitemid 30219091)
31. Edwards SJ, Campbell HE, Plumb JM. Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. Eur J Health Econ 2006;7:72-8 (Pubitemid 43375575)
32. Iakovlev SV, Beloborodov VB, Sidorenko SV, et al. Multicentre study of comparative efficacy of meropenem and combined regimens for empirical antibacterial therapy of severe nosocomial infections: results of clinical and pharmacoeconomic analysis. Antibiot Khimioter 2006; 51:15-27 (Pubitemid 47135896)
33. Barie PS, Rotstein OD, Dellinger EP, et al. The cost-effectiveness of cefepime plus metronidazole versus imipenem/cilastatin in the treatment of complicated intra-abdominal infection. Surg Infect 2004;5: 269-80 (Pubitemid 39462170)
34. Morgan CL, Kerr MP. Estimated cost of inpatient admissions and outpatient appointments for a population with epilepsy: a record linkage study. Epilepsy 2004;45:849-54 (Pubitemid 38890987)
35. Jackson BR, Thomas A, Carroll KC, et al. Use of strain typing data to estimate bacterial transmission rates in healthcare settings. Infect Control Hosp Epidemiol 2005;26:638-45 (Pubitemid 41073405)